Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico

Human Vaccines & Immunotherapeutics
Matt WassermanRaymond A Farkouh

Abstract

Pneumococcal diseases caused by Streptococcus pneumoniae represent a significant health and economic burden. Mexico has benefited from the inclusion of the 7-valent (PCV7) and 13-valent pneumococcal conjugate vaccines (PCV13) since their inclusion in the National Immunization Program (NIP) in 2006 and 2010, respectively. The objective of this study is to estimate the impact of the existing program and predict future implications of a change in the current program. A previously published model was updated to estimate the historic impact of the PCV programs relative to pre-PCV implementation. Future disease trends were forecasted based on historical serotype behaviors for each PCV13 serotype and non-vaccine serotypes across different age groups. Costs and outcomes were estimated over a 10-year period based on continued use of PCV13 compared to a switch to PCV10. The PCV7 and subsequent PCV13 NIP were estimated to prevent over 1.5 million cases of pneumococcal disease and 1,854 deaths, corresponding to a net savings of $34.50 Billion MXN. Continued use of PCV13 was estimated to save over 300 thousand cases of pneumococcal disease and 373 deaths compared to switching to PCV10 over a 10-year period. Despite a higher vaccine cost, ma...Continue Reading

References

Oct 28, 1999·PharmacoEconomics·N MittmannB A Liu
May 8, 2008·JAMA : the Journal of the American Medical Association·Jillian MongelluzzoSamir S Shah
Oct 17, 2008·The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale·Adrienne MorrowLonny James Erickson
May 21, 2009·Revista Panamericana De Salud Pública = Pan American Journal of Public Health·Maria Teresa ValenzuelaCiro A De Quadros
Feb 4, 2010·The Pediatric Infectious Disease Journal·Geneviève DeceuninckGaston De Serres
May 27, 2011·The New England Journal of Medicine·Michael C ThigpenUNKNOWN Emerging Infections Programs Network
Aug 24, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Emilio Muciño-OrtegaDavid Strutton
Apr 9, 2013·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Leila Safaee ArdekaniHamed Zare
Apr 15, 2014·The Lancet. Respiratory Medicine·Carla Magda Allan S DominguesUNKNOWN Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study Group
Jan 21, 2016·The Journal of Pediatrics·Alfredo TagarroUNKNOWN Bacteremia in Children Observation Program (BACO) Group
Feb 18, 2016·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·M J BomJ H Cornel
May 27, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Shalom Ben-ShimolRon Dagan
Feb 22, 2017·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·María Noemí Carnalla-BarajasUNKNOWN Grupo SIREVA-Mexico
Aug 8, 2017·Expert Review of Vaccines·Raul IsturizLuis Jodar
Oct 12, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joseph A LewnardRon Dagan
Apr 5, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Samuel SigurdssonÁsgeir Haraldsson
Jul 14, 2018·The Lancet Infectious Diseases·Stefanie DesmetKatrien Lagrou

❮ Previous
Next ❯

Citations

Feb 18, 2021·Journal of Biological Dynamics·Tufail M MalikElamin H Elbasha
Apr 29, 2021·Human Vaccines & Immunotherapeutics·Johnna PerdrizetMatt Wasserman

❮ Previous
Next ❯

Software Mentioned

SIREVA

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.